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Inhibition of the proteasome offers many therapeutic possibilities in inflammation as well as in neoplastic
diseases. However, clinical use of proteasome inhibitors is limited by the development of resistance or severe side
effects. In our study we characterized the anti-tumor properties of the novel proteasome inhibitor BSc2118. The
sensitivity of tumor lines to BSc2118 was analyzed in comparison to bortezomib using crystal violet staining in
order to assess cell viability. The In Vivo distribution of BSc2118 in mouse tissues was tracked by a fluorescent-
modified form of BSc2118 (BSc2118-FL) and visualized by confocal microscopy. Inhibition of the 20S proteasome
was monitored both in cultured cell lines and in mice, respectively. Finally, safety and efficacy of BSc2118 was
evaluated in a mouse melanoma model. BSc2118 inhibits proliferation of different tumor cell lines with a similar
potency as compared with bortezomib. Systemic administration of BSc2118 in mice is well tolerated, even when
given in a dose of 60 mg/kg body weight. After systemic injection of BSc2118 or bortezomib similar proteasome
inhibition patterns are observed within the murine organs. Detection of BSc2118-FL revealed correlation of
distribution pattern of BSc2118 with inhibition of proteasomal activity in cells or mouse tissues. Finally,
administration of BSc2118 in a mouse melanoma model shows significant local anti-tumor effects. Concluding,
BSc2118 represents a novel low-toxic agent that might be alternatively used for known proteasome inhibitors in
anti-cancer treatment.
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The ubiquitin-proteasome system plays a crucial role in the
maintenance of cellular homeostasis by participation in the
degradation of the majority of cytosolic proteins. This system is
involved in the regulation of the cell cycle, apoptosis, transcription,
cell signaling, antigen presentation, inflammation and development
[1]. This situation makes the ubiquitin-proteasome system to one of
the most promising therapeutic targets for further drug screening and
development.
The proteasome is an abundant cytosolic and nuclear protease
complex, which contains a 20S proteasome core complex as central
catalytic unit that harbors different proteolytic activities, i.e. a trypsin-
like (T-L within the β2 subunit), a chymotrypsin-like (ChT-L within
the β5 subunit) and a caspase-like (within the β1 subunit) [2]. Its
activity within the cell is regulated by interaction of the 20S core with
the regulatory 19S complex and with the PA28 complex at both ends of
the proteasome cylinder [3]. The proteasome system is coupled with the
ubiquitin system for controlled protein degradation [4,5]. Therefore,
inhibition of the proteasome leads in the first line to accumulation of
polyubiquitinated proteins. Imbalance in cell cycle turn over and
subsequent cell cycle arrest as well as the inhibition of NF-κB as a result
from stabilization of IκBα are other hallmarks of proteasomal inhibition.
Finally, inhibition of the 20S proteasome leads to induction of apoptosis
that is a summary effect of the inability to degrade injurious substrates.
In this context, the ChT-L activity is likely to be essential for most
proteasomal functions and for the viability of cells. Irreversible inhibition
or deletion of the β5 subunit carrying the ChT-L activity is therefore
known to be lethal [6,7].
Proteasome inhibition is an established therapeutic approach in
anti-tumor drug development. In this context, proteasome inhibitors
induce apoptosis more selectively in tumor than in normal cells,
which is the most important rationale for application of these
inhibitors in anti-tumor therapy. By stabilization of IκBα,
proteasome inhibitors exert anti-inflammatory effects and promote
death of tumor cells [8–13].
Based on the catalytic specificity of the proteasome complex, a
number of short peptide derived inhibitors (e.g., peptide boronic
acids, vinyl sulfonates or peptide aldehydes) have been developed
[14–16]. However, many of these were ultimately discarded from
consideration for clinical use because of poor stability, low
bioavailability and lack of specificity. The first drug applied in
human diseases was bortezomib, a dipeptidyl boronic acid also known
as PS-341 or Velcade (Millennium Pharmaceuticals, USA). Bortezo-
mib selectively targets the catalytic β-subunits of the proteasome in a
concentration dependent manner, thus inhibiting the chymotrypsin-
like (β5/β5i) and to a lesser degree the caspase-like (β1/β1i)
activity [17,18]. The compound was initially approved for the
treatment of drug-resistant multiple myeloma in 2003 [19].
Furthermore, this inhibitor was approved by the FDA for the
treatment of previously untreated multiple myeloma as well as
in Waldenström's macroglobulinemia and mantle cell lymphoma
[20–22]. However, prolonged treatment with bortezomib induces
substantial toxicity with frequent and potentially severe adverse
events, such as peripheral neurotoxicity, cardiotoxicity, thrombocy-
topenia, anaemia, gastrointestinal symptoms, neuropathy, fever,
fatigue, headache, arthralgia, rash as well as electrolyte disturbances
and the development of drug resistance [23–26]. Therefore, the
search for new effective and low toxic inhibitors of the proteasome
system is urgently needed.various experimental designs is MG132 (zLLL-CHO). In the present
project, we characterized the novel inhibitor BSc2118 (patent no
T30305), which is an analogue of MG132 with a better proteasome
inhibition profile than MG132 [27]. Previously, BSc2118 has been
shown to inhibit the ChTL activity of the proteasome, induce G2/M
cell cycle arrest and promote apoptosis. BSc2118 further stabilizes
IκBα and prevents NF-κB activation [27].
In the current work, we analyzed the distribution pattern of
Bsc2118 both in various tumor cell lines and in mice as well as the
inhibition profile in selected mice organs after intraperitoneal
administration. We finally show that application of BSc2118 in
mice induces local anti-tumor effects and is tolerated at higher doses
as compared to bortezomib.Material and Methods
Proteasome Inhibitors
BSc2118 and fluorescent Bodipy-BSc2118 was dissolved in DMSO
at 20 mM and kept at −20°C. Bortezomib (Lilly, Germany) was
dissolved in distilled water at 4 mM and kept at −20°C until usage.
Synthesis of BSc2118
BSc2118 was synthesized as described previously [28]. The
fluorescent variant of BSc2118 (further named as BSc2118-FL) was
synthesized as follows: a solution of 10 mg of the peptide NH2-Leu-
Asp(tBu)-Leu-CHO (BSc2118) in 1 ml dimethylformamide DMF
(pH = 8) was given to 10 mg of Bodipy-FL, SE (Molecular Probes,
Germany). The reaction mixture was stirred overnight in darkness.
Preparative purification by high-pressure liquid chromatography
(HPLC) was carried out on a Shimadzu LC-8A system with an
Agilent Zorbax, C18 SE column (250 × 21.2 mm), 7 μl, (buffer A:
0.2% trifluoroacetic acid TFA in water, buffer B: 0.2% TFA in water:
acetonitrile, 1:4). The peptides were purified with a gradient of 60%
B to 95% B in 50 min.
Cell Culture
HeLa cells and C26 murine colon cancer cells were cultured in
RPMI-1640 (Biochrom AG, Germany) with stable glutamax, both
supplemented with 10% heat-inactivated FBS (Invitrogen, Germany),
100 μg/ml streptomycin and 250 ng/ml amphotericin B (Invitrogen,
Germany). For assessment of In Vitro cytostatic/cytotoxic activity
of BSc2118, established human and mouse tumor cell lines were
used. These cells were in particular: HCT116, PC3, LoVo,
CaPan2, MDA435, Panc02, EMT6, C26, B16F10 (all ATCC)
MeWo, MeWoCis, MeWoVin, MeWoEto, MeWoFote (obtained
from Dr. H. Roekmann [29]), Mel-6, Mel-15, Mel-18, Mel-21,
MaMel-63a (obtained from Dr. D. Schadendorf, Skin Cancer
Unit Deutsches Krebsforschungszentrum, Heidelberg, Germany),
WM35, WM902B, WM9 (obtained from Dr. M. Herlyn,
Wistar Institute, Philadelphia, PA). All cells were grown either in
DMEM or in RPMI-1640 and supplemented with 10% FCS
plus antibiotics.
Estimation of GI50 (growth inhibition) of BSc2118 in a panel
of tumor cell lines
The influence of BSc2118 on the growth of 22 tumor cell lines was
analyzed using a crystal violet assay similarly as described for
bortezomib by Adams et al [30]. GI50 is defined as the concentration
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cells. Briefly, cells were seeded in quadruplicates on 96-well plates,
exposed for 48 hours to proteasome inhibitors in 7 dilutions ranging
from 10 nM to 1000 nM (for BSc2118) and from 1 nM to 100 nM
(for bortezomib). The cytostatic/cytotoxic effects of both BSc2118
and bortezomib on treated cells were compared to that of control
cells. The mean viability for the whole cell panel was calculated in two
ways, thereafter. First, average viability for the entire panel was
calculated for each concentration point followed by calculation of the
average GI50 value. Second, GI50 was averaged for each cell line
individually. Both methods of calculation resulted in similar results.
Isolation and Activity Measurement of 20S Proteasomes
20S proteasomes were isolated from both red blood cells of healthy
volunteers and from murine organs [31]. Lysates from murine organs
after injection of inhibitors were obtained by homogenization in 100
mM HEPES, pH 7.4, 2 mM MgCl2, 0.1% NP-40, 5 mM
dithiothreitol and completed by Ultra-Turrax T8 (IKA-Werke).
Chymotrypsin-like activity of the 20S proteasome was measured with
a fluorogenic substrate (Suc-LLVY-AMC, Bachem, Germany).
Briefly, 100 ng of purified proteasomes were exposed to proteasome
inhibitors (0-1000 nM) and incubated with 50 μM of fluorogenic
substrate for up to 60 min. Lysates normalized to protein content
were directly incubated with 50 μM of fluorogenic substrate. The
fluorescence was measured with POLARstar reader (BMG Labtech,
Germany). The excitation and emission wavelengths were 390 nm
and 460 nm, respectively. All experiments were performed in
quadruplicates and repeated at least three times. Differences between
groups were calculated by a Student’s t test. A P value of b0.05 was
considered to be statistically significant.
The Influence of Microsomal Enzymes on Inhibitor Stability
For analysis of inhibitor stability in the presence of microsomal
enzymes, BSc2118 and MG132 (at 0.1 to 5 μM, respectively) were
incubated with mouse (Balb/c) microsomes (GIBCO) for up to
24 hours according to manufacturer instructions. The proteasome
activity (20S isolated from mouse muscles) was measured in the
presence of inhibitors with/without microsomal fraction as described in
the section above. The results are displayed as relative 20S activity in the
presence of inhibitors incubated with microsomal fraction. Inhibitors
incubated with PBS were defined as 100%. The data are displayed as
decrease of inhibitory activity in the presence of microsomal enzymes.
Differences between groups were calculated by Student’s t test. A
P value of b0.05 was considered to be statistically significant.
Immunoblot Analysis
The procedure has been described previously [27]. The poly-
ubiquitinated proteins were detected with a polyclonal rabbit anti-
ubiquitin antibody (Dako, Germany), and GAPDH was detected
using a monoclonal anti-GAPDH (glyceraldehyde 3-phosphate
dehydrogenase) antibody (Santa Cruz, Germany). A peroxidase-
coupled anti-rabbit or anti-mouse antibody was used as secondary
antibody (Jackson Immunoresearch, UK).
Incubation with BSc2118-FL and Confocal Microscopy
HeLa cells and C26 cells were directly incubated with BSc2118-FL,
washedwith PBS, fixed with 70% ethanol and probedwith either rabbit
anti-proteasome antibody (anti α4 subunit, Inst. for Biochemistry,
Charité, Berlin, Germany) or with a mouse anti-ubiquitin conjugatedantibody FK1 (Biomol, Germany). After washing, they were probed
with secondary antibodies coupled with a fluorescent dye such as FITC
or Alexa-fluor 540 (Jackson Immunoresearch, UK). All antibody
solutions were made up in PBS containing 5% bovine serum albumin.
Actin filaments were stained by incubation for 1 hour with Phalloidin
coupled to Atto647N (Sigma Aldrich, Germany). Cell nuclei were
visualized by stainingwithDAPI (SigmaAldrich,Germany). Specimens
were embedded in Vecta shield medium (Reactolab SA, Switzerland).
The sections were examined with a Leica confocal laser scanning
microscope (Leica Microsystems, Germany) equipped with a
krypton-argon laser. Sequential scans at a series of optical planes
were performed with a 63× oil immersion objective lens through
specimens.
Experimental Design for In Vivo Studies
Female C57BL/6 and BALB/c mice, 8 to 12 weeks of age, were
obtained from the Animal House of the Polish Academy of Sciences,
Medical Research Center (Warsaw, Poland). All In Vivo experiments
were performed according to EU guidelines for the care and use of
laboratory animals and approved by local authorities. The inhibitor
BSc2118 was administered intraperitoneally (i.p.) in 50 μl DMSO or
intratumorally (i.t.) in 20 μl DMSO. As controls, mice were treated
with appropriate volumes of DMSO. Bortezomib was given to mice
at 1 mg/kg i.p. in 50 μl PBS, for which mice treated with 50 μl PBS
i.p. served as controls.
For studies on biodistribution and kinetics of inhibitors, BALB/c
mice received one single dose of inhibitor at 5 and 10 mg/kg. After 1
hour or 24 hours post injection, mice were sacrificed; tissue samples
were collected and divided into halves. For direct observations of
BSc2118-FL tissue samples were embedded in OCT and immedi-
ately frozen at −70°C. For biochemical analysis, tissue samples were
frozen at −70°C and kept until preparation. An initial study was
carried out in melanoma bearing C57BL/6 mice to determine the
potency of BSc2118 to inhibit the proteasome activity In Vivo either
within red blood cells or within tumor tissue after i.t. or i.p. injection
of the inhibitor.
Melanoma Anti-Tumor Therapy in Mice by BSc2118
Female C57BL/6mice of 8 to 9 weeks of age were inoculated into the
footpad on day 0 with 1 × 106 B16F10 cells in 20μl of PBS. Tumor cell
viability measured by trypan blue exclusion was above 98%. Beginning
fromday 7 after inoculation,melanoma bearingmice were injectedwith
5, 10, or 15mg per kg body weight of BSc2118 in a volume of 20 μl i.t.
for 7 consecutive days. For i.p. injection protocols, BSc2118 was given
at dose of 15, 30, or 60 mg per kg body weight for seven consecutive
days. Bortezomib was given at 1 mg/kg i.p. 7 times every second day.
Each group contained 7 animals. Appropriate volumes of the solvents
were given as control. During the experiments melanoma bearing mice
were observed daily for survival and adverse effects. Tumor size of
melanoma-bearingmice wasmeasured every 2 days. Tumor volumewas
determined according to the formula: tumor volume = (shorter
diameter2 × longer diameter)/2. Differences in tumor volume were
analyzed for significance by the Student’s t test. A P value of b0.05 was
considered to be statistically significant. Log-rank test was used to
analyze survival.
In Vivo Angiogenesis Assay
Mice were anesthetized and received sterile abdominal injections of
250 μl of Matrigel (Becton Dickinson, Germany) subcutaneously
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were i.p. treated with BSc2118 at 30 mg/kg for 7 consecutive days. At
day 8, vascularization of the Matrigel was quantified by intravenous
injecting of 0.1 ml (0.25 mg/ml stock solution) of FITC-dextran
(125,000 molecular weight, Sigma Aldrich, Germany) into mice,
which allowed blood vessels within plugs to be visualized. Animals
were sacrificed 20 minutes after injection, when Matrigel plugs were
removed and digested in Dispase reagent (Becton Dickinson,
Germany). The fluorescence of the solution obtained was measured
using a fluorimeter (POLARstar, BMG Labtech, Germany) with an
excitation at 480 nm and an emission wavelength at 520 nm.
Differences between groups were calculated by Student’s t test. A
P value of b0.05 was considered to be statistically significant.
In Vivo Metastasis Assay
Experimental lung metastases were performed as described by
Feleszko et al. [32]. Briefly, experimental lung metastases were
induced by injection of 2 × 105 of B16F10 cells/100 μl PBS into the
tail vein of anesthetized female C57BL/6 mice. Mice (5 to 7 per
group) were i.p. injected for 7 consecutive days with either DMSO or
BSc2118 (15 mg/kg body weight/day). The animals were then
sacrificed on day 21 after inoculation of tumor cells. An average
number of metastases were calculated for every mouse by two
independent observers blinded to the experimental groups. Differences
between experimental groups were analyzed using the Mann–Whitney
U test. A P value of b0.05 was considered to be statistically significant.
Results
BSc2118 is Cytotoxic for a Panel of Solid Tumor Cell Lines
An In Vitro cytotoxicity screening was performed to characterize
the anti-tumor potential of BSc2118. For this purpose, a panel of
solid tumor cell lines, most of them originating from malignant
melanoma, was incubated either with BSc2118 or with bortezomib as
a reference inhibitor (Figure 1). The average GI50 value was estimated
for each cell line and across the entire tumor cell panel. We found an
average GI50 value of 76 nM for BSc2118, whereas the average GI50
value for bortezomib across 22 cell lines was 6.3 nM. For comparison,
on NCI cell panel the GI50 value for bortezomib was given at 7 nMFigure 1. BSc2118 affects viability of 22 tumor cell lines. Graphs
were prepared by averaging viability of 22 cell lines from seven
concentration points of inhibitors. Results are displayed as
percentage of controls. The discrepancy in the concentrations of
inhibitors is a result of different Ki-values for both drugs.[30]. Figure 1 shows average viability for seven concentrations as
percentages regarding controls for both BSc2118 and bortezomib.
Characterization of Inhibitory Properties of BSc2118
and BSc2118-FL
The proteasome inhibitor BSc2118 was described previously by
Braun et al. [28]. To better track the biological properties of thisigure 2. Characteristics of BSc2118-FL. (A) Chemical structure of
Sc2118 and BSc2118-FL. The arrow indicates the position of
ovalent modification by binding of the fluorescent group (Bodipy
L C5). (B) Comparison of 20S inhibition profiles of parental
Sc2118 and its modified version BSc2118-FL within HeLa cells.
he error bars (SD), best visible at 0 and 10 nM, at the other points
re very small. (C). Confocal microscopy of C26 colon cancer cells
cubated for 24 hours with BSc2118-FL (1 μg/μl). (I) Direct
luorescence signal of BSc2118-FL (green), (II) antibody-mediated
taining against the 20S proteasome (red), (III) antibody-mediated
taining against ubiquitin (magenta). BSc2118-FL co-localizes with
tracellular 20S proteasome and ubiquitin. Nuclei were stained with
API (IV). Merged photo is shown in (V). (D). Accumulation of
olyubiquitin conjugates in soluble fraction obtained fromC26 colon
ancer cells after 24 hours of exposure to 130 nM FL-BSc2118 (+)
ompared to cell fractions from non-treated cells (−) using Western
lotting. (E) BSc2118-FL (green, 500 nM for 24 h) induces apoptosis
C26 colon cancer cells as shown by morphological analysis.
uclear staining with DAPI is shown in blue. Scale bar: 15 μm.F
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Figure 4. Analysis of stability of BSc2118 in microsomal fraction.
Relative stability of indicated inhibitors (at 500 nM each) in the
presence of liver microsomal fraction is shown. BSc2118 is more
stable in liver microsomal fraction in comparison to MG132.
*Significant difference between BSc2118 and MG132 in the
indicated time point (*P b 0.05).
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this molecule (Figure 2A). The Bodipy FL-BSc2118 (thereafter
named as BSc2118-FL) inhibited proteasome activity similarly to
non-fluorescent BSc2118 in HeLa cells (Figure 2B), suggesting that
this chemical modification does not change the inhibitory properties
of the compound. A 24-hour incubation of HeLa cells with 1 μg/ml
of BSc2118-FL resulted in formation of aggregates that co-localized
with both ubiquitin and the proteasome (Figure 2C). Furthermore,
we found an accumulation of polyubiquitinylated proteins after
24 hours of incubation of C26 cells with BSc2118 as indicated by
Western blotting (Figure 2D). Like the non-fluorescent compound,
BSc2118-FL induces apoptosis in C26 colon cancer cells as
exemplarily shown in (Figure 2E).
Analysis of inhibition of proteasomes derived from different
murine tissues revealed that BSc2118 is sufficient to inhibit 20S
activity in a concentration dependent manner in all organs analyzed
(Supplementary Figure 1).
BSc2118 and BSc2118-FL Inhibit 20S Activity In Vivo
We next analyzed the inhibition of 20S proteasomal activity induced
by BSc2118 as compared to bortezomib InVivo. For this purpose, mice
were i.p. injected with either BSc2118 or bortezomib at different
concentrations followed by sacrifice of mice after 1 hour or 24 hours
post-injection. Lung, heart, spleen, liver, kidney, skeletal muscle, brain
and bloodwere collected for each time point. A dose of at least 10mg/kg
of BSc2118 was sufficient to inhibit 20S activity in mice organs
(Figure 3). One hour after injection of BSc2118 (30 mg/kg), the
proteasome activity was reduced to 15% or less in all organs with the
exception of the brain and the kidney (Figure 3). Nevertheless, atFigure 3. Inhibition of proteasome activities in different tissues after
both BSc2118 (BSc) and bortezomib (Bor) yield similar inhibitory patte
of controls (abbreviated as “C”). All controls have received respective
significant differences, thus for better visibility one bar for averaged
boxes) or after 24 hours (striated boxes) post-injection, respectively. S24 hours post-injection 20S activities recovered from 60% up to 100%
as compared to controls (Figure 3). Similar inhibition patterns were
shown for bortezomib (Figure 3) with a reduction of 80% to 90%
at 1 hour following its inoculation in most organs. In the brain,
however, only a 10% reduction of 20S proteasome activity at 1 hour
after treatment was observed, whereas 24 hours after treatment 20S
activity was found to be inhibited about 20%. In contrast to other
tissues, no recovery of proteasome inhibition 24 hours post-
injection was detected within the brain. In line with this, BSc2118-intraperitoneal administration of inhibitors in mice. Application of
rns of the 20S proteasome activity, which is given as relative activity
ly: DMSO or 0.9% NaCl at both time points and did not show any
controls is shown. Mice were sacrificed either after 1 hour (grey
ignificantly different from controls with *P b 0.05 and **P b 0.005.
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after i.p. administration (Supplementary Figure 2). In the selected
organs, there was a strong 20S inhibition after 1 hour, whereas after
24 hours proteasomal activity was almost completely restored.None of the BSc2118-treated animals (n = 7) demonstrated any
signs of toxicity that could be identified by observation. No weight
loss, diarrhea, hair loss, or neurological symptoms (like tremor, ataxia,
paralysis) were observed in BSc2118-treated mice, even if mice were
treated daily with a 60 mg/kg dose for 7 consecutive days. In mice
treated with bortezomib the drug was administered at 1 mg/kg every
second day. Animals that were given higher daily doses of bortezomib
died on day three after start of treatment (data not shown).
Concluding, BSc2118 inhibits the proteasome activity In Vivo to a
similar extend as bortezomib (Figure 3), but is better tolerated and
less toxic in spite of daily administration.
Analysis of Stability of the BSc2118AgainstMicrosomal Proteases
Some proteasome inhibitors like MG132 become instable in
presence of microsomal fractions due to various mechanisms
involving binding or modification. To analyze the resistance of
BSc2118 against microsomal proteins, measurement of 20S
inhibitory activity in the presence/absence of liver microsomes was
performed. As shown in Figure 4, BSc2118 is stable for up to 4 hours
of incubation with microsomes. After 8 hours of incubation with liver
microsomes, there is an observed 30% loss of inhibitory activity.
Thus, BSc2118 turned out to be more stable than MG132, which
lost its activity at 4 hours in a dose and time dependent manner, i.e.,
50% of activity loss at 4 hours and 70% of activity loss at 8 hours,
After 24 hours of treatment, the activity loss for both MG132 and
BSc2118 was comparative.
Analysis of Biodistribution Using BSc2118-FL
To track the biodistribution of BSc2118, the Bodipy-labeled
BSc2118 (BSc2118-FL) was directly analyzed in tissue sections
detecting spontaneous fluorescence by means of confocal microscopy.
In order to achieve sufficient direct fluorescence signal, dosages of
BSc2118-FL had to be at least 10 mg/kg body weight. Although
dosages of 5 mg/kg body weight significantly inhibited 20S activities
and induced accumulation of polyubiquitinated proteins, spontane-
ous fluorescence signal was too weak for direct observations (data not
shown). The fluorescence within erythrocytes mounted after 1 hour
or 24 hours post i.p. injection (10 mg/kg) is depicted in (Figure 5A).
Erythrocytes (0 h) from vehicle injected mice served as control to
visualize the autofluorescence signal of hemoglobin. The inhibitor-
specific fluorescence was most pronounced in animals at 1 hour after
inhibitor injection. After 24 hours the fluorescence intensity was
approximating the baseline due to inhibitor fluorescence instability or toFigure 5. Detection of fluorescence intensities of BSc2118-FL after
In Vivo administration. (A) Left panel: direct observations of
fluorescence within red blood cells isolated either from untreated
mice (0 h) or after 1 hour or 24 hours post-administration of
BSc2118-FL (10 mg/kg) in mice. Right panel: phase contrast
pictures of erythrocytes from left panel. Scale bars: 15 μm.
(B) Observations of BSc2118-FL direct fluorescence by means of
confocal microscopy within the small intestine (I), heart (II) and
kidney (III), which were isolated frommice injected with BSc2118-FL
at 10 mg/kg (left panel) or treated with vehicle (right panel). Internal
organs were collected after 1 hour and 24 hours post-inhibitor
injection. Scale bars: 50 μm. (C) Western blotting for detection of
polyubiquitin conjugates in lysates from organs after i.p. injection of
BSc2118 or Bortezomib. Time points given refer to time of injection
of inhibitors. Controls (C) were injected with vehicle and here one
representative control is shown. GAPDH (here exemplary shown in
the liver) served as loading control.
Figure 6. Comparison of proteasome inhibition after intraperitoneal
and after intratumoral injectionofBSc2118 in amouseB16F10 tumor
model. ChT-L activity was determined either in melanoma homog-
enates (A-B) or in red blood cells (C-D) after intraperitoneal (i.p.; A and
C) or intratumoral (i.t.; B and D) injection of BSc2118. Each diagram
displays bars as follows: activity in vehicle treated controls
(C), activity 1 hour post-injection and 24 hours post-injection of
BSc2118. Controls were defined as 100%. (E) Western blot analysis
of polyubiquitynated proteins from tumor lysates displayed in (A-B).
Accumulation of polyubiquitinylated proteins correlates with protea-
some inhibition profile displayed in A and B. Significantly different
from controls with *P b 0.05 and **P b 0.005.
576 Anti-tumor Efficacy of BSc2118 Mlynarczuk-Bialy et al. Translational Oncology Vol. 7, No. 5, 2014the low reversibility of Bodipy-BSc2118. In organs, bright specific
BSc2118-FL fluorescence was observed exemplarily in intestine (I),
heart (II) and in proximal tubules of kidney (III) (Figure 5B).
Remarkably, no fluorescence was observed in intact brain (not shown),
confirming the 20S activity data of brain lysates included in Figure 3.
To further demonstrate the In Vivo effects of proteasome
inhibition, we examined tissue lysates for polyubiquitin conjugates
using Western blotting (Figure 5C). In blood and liver there was an
accumulation of polyubiquitin conjugates observed that correlated
with proteasome inhibition displayed in Figure 3. In the brain,
however, a constitutive high amount of polyubiquitin conjugates was
detected that did not increase upon administration of inhibitors. A
moderate accumulation of polyubiquitin was only found in brain
homogenates after 24 hours of BSc2118 treatment.
BSc2118 Exerts Local Anti-Tumor Effects in a Mouse
Melanoma Model
Proteasome inhibitors are approved for use in the treatment of
multiple myeloma and mantle cell lymphoma. Moreover, a number
of clinical studies investigated the anti-tumor effects of bortezomib in
patients with solid tumors. Therefore, we decided to compare
potential anti-tumor effects of BSc2118 to bortezomib in the
B16F10 melanoma model in mice (Figure 6). First, we compared the
efficiency of BSc2118 to inhibit the 20S activity directly within
tumor tissues after i.t. or i.p. administration. The inhibition in tumor
tissues was compared to the inhibition in red blood cells. After i.p.
administration of BSc2118 (30 mg/kg),the activity of 20S proteasomes
was reduced by up to 65%within tumors whenmeasured at 1 hour post-
injection. However, the 20S proteasome activity recovered to control
levels within 24 hours (Figure 6). BSc2118 when given i.t. (10 mg/kg)
almost completely inhibited 20S proteasome activity at 1 hour after
administration. Activities also remained inhibited by 90% during the
following 24 hours. BSc2118 given i.p. reduced the 20S activity in blood
cells of mice bearing melanoma (Figure 6) similarly to healthy ones
(Figure 3), i.e. there was an initial reduction of 20S activity in the 1-hour
group that increased in the 24-hour group. After i.t. injection of BSc2118,
the initial inhibition of the 20S proteasome in the 1 hour groups was 40%
and it dropped towards 50% in the 24-hour groups. Taken together with
proteasome inhibition within erythrocytes after i.t. injection of BSc2118,
there is an evidence that at least half of the initial proteasome activity is
still inhibited within the tumor after 24 hours post-injection and that
the inhibitor is slowly released from the place of injection. The activity
data correlated with accumulation of polyubiquitin conjugates within
tumors that are shown in Figure 6E.
Tumor size or survival of treated mice after i.p. administration with
either BSc2118 or bortezomib was, however, not affected by the
inhibitors (data not shown). On the contrary, when BSc2118 was
administered i.t. at a 5mg/kg dose, a complete tumor regression was
observed, which led to prolonged animal survival for up to two months
(Figure 7, A–B). Unexpectedly, when BSc2118 was injected i.t. at 10 or
15 mg/kg doses, a significant local toxicity (edema and ischemia) was
observed in 30% of animals that precluded further analysis of tumor
growth (Figure 7, A–B).
To better characterize potential mechanisms of anti-tumor action of
BSc2118, a metastasis assay as well as a matrigel angiogenesis assay were
performed. For these assays, BSc2118 had to be i.p. administered for
technical reasons, yielding no optimal inhibition of the 20S proteasome
within the 24-hour animal groups. Nevertheless, animals treated with
BSc2118 at 30 mg/kg revealed a tendency to reduce the number ofmetastases as compared to controls (Figure 7C). In spite of a tendency of
BSc2118 (30 mg/kg) to reduce angiogenesis, significant results were
lacking (Figure 7D; P = 0.06). Taken together, BSc2118 exerts local
antitumor activity in a mouse melanoma model.
Discussion
Novel proteasome inhibitors are intensively developed and studied in
order to find more specific and safer inhibitors with a broad spectrum of
therapeutic applications [15,33–35]. In this context, we studied for the
first time the biodistribution of the novel proteasome inhibitor BSc2118
In Vivo followed by an analysis of its therapeutic potential and
therapeutic safety in the context of malignant melanoma.
For inhibitor tracking in living organisms, the fluorescent variant of
BSc2118, BSc2118-FL, was synthesized. BSc2118-FL was cell-
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proteasome and had a similar inhibition profile in comparison to its
non-fluorescent variant. The bright fluorescence signal facilitated rapid
and sensitive detection of proteasomes by fluorescence-based micros-
copy in living cells and in tissues. Because the proteasome inhibitor
BSc2118 had a low toxicity, even the use of higher concentrations thatallows monitoring of inhibitor biodistribution, was well tolerated in
experimental models.
The biodistribution and inhibition profile of proteasomes
inhibited by BSc2118 in a mouse model was compared to bortezomib
and was similar in equivalent concentrations. BSc2118 was given
daily at maximal doses of 60 mg/kg body weight for 7 days, which was
well tolerated by mice with no signs of toxicity. Using this application
schedule, no lethality was observed. Moreover as it was shown in a
different publication, BSc2118 up to 60 mg/kg daily dose did not
affect peripheral blood morphology in C57BL/6 mouse [36]. In
contrast, bortezomib had to be given with at least a one-day break,
whereas daily injection of 1 mg/kg body weight was lethal in most
animals. As such, BSc2118 might serve as a potential, low toxic and
well tolerated novel drug [30].
Therefore, we analyzed the potential for BSc2118 usage in
different application forms to be considered for proteasome
inhibition. These typically include anti-tumor effects based on cell
cycle arrest and on inducing apoptosis [34,35]. Although Bortezomib
was developed and approved for therapy of multiple myeloma and
mantle cell lymphoma only, therapeutic potential for other tumors
was investigated within the last years as well [37]. However,
bortezomib was not effective in treatment of solid tumors until
recently [38]. BSc2118 tested on a panel of 22 tumor cell lines
derived from solid tumors exerted cytotoxic and cytostatic effects with
a GI50 of 76 nM, whereas for bortezomib 6.3 nM was calculated. Due
to different Ki-values for both inhibitors, previously data has shown
that concentration ratios giving similar 20S inhibition patterns for
BSc2118 and bortezomib is 10:1 [27]. Thus, compilation of equally
potent concentrations of both BSc2118 and bortezomib revealed that
these inhibitors comparatively inhibit growth of the 22 tumor cell
lines analyzed.
BSc2118 and BSc2118-FL induce both accumulation of polyubi-
quitin conjugates and apoptosis in a broad spectrum of cells, as has been
exemplarily shown in C26 colon cancer cells. Efficiency of inhibitors in
organisms is highly dependent on bioavailability, stability and
reversibility of the compounds. BSc2118 is partially instable in liver
microsomal fraction. Whereas Bortezomib is irreversible, binding of
BSc2118 is reversible [36]. Proteasome inhibition induces com-
pensatory De Novo synthesis of proteasomes [39]. Whereas
reversible inhibition affects more proteasomes in cells positively
correlating with exposition time (binding-dissociation-rebinding),
more stable inhibition rather acts like a pulse inhibition. This means
that cells which are able to compensate proteasome inhibition viaFigure 7. Anti-tumor effects of BSc2118. (A) BSc2118 induced
significant melanoma tumor growth retardation in mice treated i.t.
with BSc2118 at 5 mg/kg for up to 40 days of treatment. BSc2118
at 10 mg/kg and 15 mg/kg induced foot loose in 3 mice at day 19.
(B) Kaplan-Meier curves showing survival comparison between
control and drug-treated mice. Log-rank test showed significant
difference in survival time among all treated groups compared to
controls at P b 0.0005. (C) In Vivo melanoma lungmetastases assay
displaying a trend towards reduced numbers of lung metastasis
due to treatment with BSc2118 (30 mg/kg). Horizontal lines show
means from 7 displayed points. (D) Indirect In Vivo assessment of
angioneogenesis within matrigels followed by staining of blood
vessels with dextran FITC. Mean fluorescence of matrigels are
displayed on y-axis and corresponds to the number of blood
vessels. There was a trend towards a reduction of fluorescence
intensity detectable in BSc2118-treated mice.
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so suffer from UPR stress and accumulation of oxidized proteins
[40]. In this context, the majority of tumor cells are more sensible
to proteasome inhibition than their parental cells [27].
In order to study possible therapeutic potentials of BSc2118, we
studied BSc2118-mediated effects in a mouse model of malignant
melanoma. BSc2118 in experimental melanoma therapy revealed
some unexpected findings. First of all, neither BSc2118 nor
bortezomib injected i.p. had any effects on tumor growth or survival
of B16F10 tumor bearing mice (data not shown). It is known that
tumor tissue has its own milieu and drugs working well In Vitro
might not be effective In Vivo due to the existence of the tumor
matrix [41]. Therefore, the inhibitor was injected directly into the
tumor. Comparison of proteasome inhibition profiles after both i.p.
and i.t. injection of BSc2118 revealed that BSc2118 completely
inhibited proteasome activity after i.t. injection, which lasted for at
least 24 h. This result prompted us to check the effects of BSc2118 on
tumor growth when injected i.t. We obtained tumor growth
retardation and complete remission with a survival for up to two
months in 38.5% of mice receiving BSc2118 from all experimental
groups. However, BSc2118 at 10 and 15 mg/kg induced local
toxicity, suggesting that local levels of proteasome inhibition within
the tissue should not exceed 80%. On the contrary, increased
proteasome inhibition might be toxic as has been demonstrated for
bortezomib in primates [42]. In humans the inhibition of 20S activity
with bortezomib does not exceed 70% [43].
To better characterize the mechanisms of action of BSc2118 in a
tumor model we studied BSc2118-mediated De Novo angiogenesis
and metastasis in a model of malignant melanoma. Noteworthy, our
experimental model needed i.p. injections of BSc2118 that might not
induce satisfactory level of proteasome inhibition and had no effects
on tumor growth. However, in this application design there was a
tendency at the border of significance to reduce the number of
metastases and De Novo arising blood vessels. It seems that BSc2118
retards tumor growth by means of 20S inhibition within tumor cells
and additionally might reduce both metastasis and angiogenesis.
In conclusion, we characterized a novel proteasome inhibitor that
has a similar proteasome inhibition spectrum compared to
bortezomib In Vitro and In Vivo, but has under the conditions
tested less signs of toxicity. We hypothesize that BSc2118 is a
therapeutic alternative to bortezomib in therapy of solid tumors, for
which further studies will be needed.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.tranon.2014.07.002.
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